Life Science Investing TScan Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Life Science Investing TScan Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
Life Science Investing TScan Therapeutics Reaches Agreement with FDA on Pivotal Study Design for TSC-101 and Announces Strategic Prioritization to Advance TSC-101 and Extend Cash Runway into H2 2027
Life Science Investing TScan Therapeutics Announces Upcoming Oral and Poster Presentations at the American College of Rheumatology Convergence 2025
